Notably, we first prove the TRIM29-STING regulatory axis during NASH progression, which also favors that factors involved in innate immunity might be potential therapeutic targets for NASH treatment. This evidence concerns the gene TRIM29 and metabolic dysfunction-associated steatohepatitis.